Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | HRH2 | P25021 | 4/20 | 0.70 |
| ▸ | HRH1 | P35367 | 4/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981478 | 0.87 | KDM4E (0.89) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL5213285 | 0.87 | KDM4E (0.89) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL491803 | 0.86 | KDM4E (0.92) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL5855860 | 0.84 | KDM4E (0.90) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL9200735 | 0.84 | HRH3 (0.72) | HRH2HRH1HRH3ALDH1A1MEN1 | |
| SCHEMBL9530115 | 0.83 | ALDH1A1 (0.81) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL7242885 | 0.83 | HRH3 (0.77) | HRH2HRH1HRH3 | |
| SCHEMBL7244138 | 0.82 | HRH2 (1.00) | HRH2HRH1 | |
| SCHEMBL9664644 | 0.82 | KDM4E (0.68) | KDM4EHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL491570 | 0.82 | HRH3 (0.72) | KDM4EHRH2HRH1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559140-B2 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBOTT LABORATORIES | 2003-05-06 | — | — | US | disclosed |
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | ABBVIE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001066534-A2 | CYCLIC AND BICYCLIC DIAMINO HISTAMINE-3 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049367-A1 | Cyclic and bicyclic diamino histamine-3 receptor antagonists | HRH4, HRH2, HRH3 | KDM4E 2636/4885HRH2 2/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.